Title	The New Dimensions of Warfarin Prophylaxis [electronic resource] / edited by Stanford Wessler, Carl G. Becker, Yale Nemerson
Imprint	Boston, MA : Springer US : Imprint: Springer, 1987
Connect to	http://dx.doi.org/10.1007/978-1-4757-5985-3
Descript	IX, 329 p. online resource

The International Symposium on The New Dimensions of Warfarin Prophylaxis held on October 16-18, 1986 in New York City was conceived as a forum to bring together physicians and other scientists knowledgeable about the pharmacological effects of warfarin on the hemostatic mechanism and the clinical usefulness of this compound in the prevention of thromboembolic phenomena. The coumarin compounds have commanded a striking breadth of interest among members of the biomedical research community for almost one-half century. Aspects of its effects on the vitamin K-dependent proteins, on the laboratory recognition of the drug's pharmacologic action and its use as a therapeutic agent in a variety of disease states have been actively studied with increasing intensity in the past several decades. Thus, the present state of these studies seemed to be a timely subject for discussion, not only to gather together in one place representative samples of the myriad of data on warfarin, but also to underscore the ever increasing necessity for communication between basic research and clinical practice. The content and organization of this monograph reflect the scope and importance of warfarin prophylaxis. One of the unique aspects of this publication is that it spells out in one place the warfarin story from molecular biology through clinical trials to future directions of research and patient care

The Scope of Thromboembolism -- Vitamin K-Dependent Proteins -- The Biochemical Basis of Warfarin Therapy -- Warfarin and the Biochemistry of the Vitamin K Dependent Proteins -- Anticoagulation Proteins C and S -- Warfarin and Bone: Implications for Rational Strategies to Selectively Antagonize the Action of Vitamin K in Target Tissues -- Human Genes for Factor IX and Other Vitamin K Dependent Blood Proteins -- The Prothrombin Time -- Tissue Factor -- INR โ{128}{148} Calibration of the Therapeutic Range -- Cold-Promoted Activation of Factor VII and Shortening of the Prothrombin Time -- Immunologic Aspects of Vessel Injury and Thrombosis -- Whatโ{128}{153}s The Dose? -- Venous Thromboembolism โ{128}{148} Primary Prophylaxis -- Venous Thromboembolism in Moderate Risk Patients -- Two-Step Warfarin Therapy for the Prophylaxis of Venous Thrombosis after Elective Surgery -- Prevention of Venous Thromboembolism in High-Risk Patients by Prophylactic Administration of Oral Anticoagulants -- Genetic Coagulation Defects -- Venous Thromboembolism โ{128}{148} Secondary Prophylaxis -- Treatment of First Episode of Venous Thrombosis -- Management of Recurrent Venous Thromboembolism -- Special Issues -- Warfarin Metabolism and Drug-Drug Interactions -- Improving the Benefit/Risk Ratio -- Oral Anticoagulant Therapy and Skin Necrosis: Speculations on Pathogenesis -- Cardiovascular โ{128}{148} Arterial Thromboembolism -- Clinical Trials in Myocardial Infarction and Coronary Heart Disease -- Anticoagulants in Acute Myocardial Infarction -- Long-Term Anticoagulant Treatment after Acute Myocardial Infarction -- Following Coronary Thrombolysis -- Arterial Thromboembolism: Valvular Heart Disease and Prosthetic Heart Valves -- Neurovascular โ{128}{148} Arterial Thromboembolism -- Clinical Trial Dilemmas and Cerebrovascular Disease -- Atrial Fibrillation and Stroke: The View from Cardiology -- Atrial Fibrillation and Stroke: The View from Neurology -- Cardiac Embolic Stroke: Anticoagulating the Elderly -- Anticoagulants for the Treatment of Transient Ischemic Attacks -- Epilogue -- Contributors